TG Therapeutics will present BRIUMVI (ublituximab-xiiy) data at the American Academy of Neurology 2026 Annual Meeting on April 21, 2026, in Chicago, Illinois. The abstracts are available at https://www.aan.com/events/annual-meeting-abstracts. After the presentations, related materials will be posted at https://www.tgtherapeutics.com/publications. More information on BRIUMVI is available at https://www.briumvi.com.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TG Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603060730PRIMZONEFULLFEED9667160) on March 06, 2026, and is solely responsible for the information contained therein.